New Tests Promise to Help Improve Diagnosis and Treatment of Herpes Patients

Clinicians may soon have a new tool in the diagnosis and treatment of Herpes Simplex Viruses – one of the most common sexually transmitted infections in the world. BD Diagnostics, a segment of BD (Becton, Dickinson and Company) BDX, announced today that it filed for U.S. Food and Drug Administration (FDA) 510(k) clearance for the first fully automated molecular tests to diagnose and differentiate HSV types 1 and 2.